.Attributes Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- drug conjugate (ADC) tisotumab vedotin caused enhanced progression-free as well as total survival, triggering FDA approval as well as a brand-new therapy option for patients.